Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PTPN11 mutation
i
Other names:
PTPN11, Protein Tyrosine Phosphatase Non-Receptor Type 11, Tyrosine-Protein Phosphatase Non-Receptor Type 11, Protein-Tyrosine Phosphatase 1D, Protein-Tyrosine Phosphatase 2C, SH-PTP2, SH-PTP3, PTP-1D, PTP2C, Protein Tyrosine Phosphatase Non-Receptor Type 11, Noonan Syndrome 1, METCDS, PTP-2C, SHPTP2, BPTP3, SHP-2, JMML, SHP2, Shp2, CFC, NS1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5781
Related biomarkers:
Expression
Mutation
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
PTPN11 mutation
Acute Myelogenous Leukemia
PTPN11 mutation
Acute Myelogenous Leukemia
gilteritinib
Resistant: B - Late Trials
gilteritinib
Resistant
:
B
gilteritinib
Resistant: B - Late Trials
gilteritinib
Resistant
:
B
PTPN11 mutation
Juvenile Myelomonocytic Leukemia
PTPN11 mutation
Juvenile Myelomonocytic Leukemia
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
PTPN11 mutation
Acute Myelogenous Leukemia
PTPN11 mutation
Acute Myelogenous Leukemia
LY3009120
Sensitive: C3 – Early Trials
LY3009120
Sensitive
:
C3
LY3009120
Sensitive: C3 – Early Trials
LY3009120
Sensitive
:
C3
PTPN11 mutation
Acute Myelogenous Leukemia
PTPN11 mutation
Acute Myelogenous Leukemia
venetoclax
Resistant: C3 – Early Trials
venetoclax
Resistant
:
C3
venetoclax
Resistant: C3 – Early Trials
venetoclax
Resistant
:
C3
PTPN11 mutation
Acute Myelogenous Leukemia
PTPN11 mutation
Acute Myelogenous Leukemia
cytarabine + daunorubicin + mitoxantrone
Sensitive: C3 – Early Trials
cytarabine + daunorubicin + mitoxantrone
Sensitive
:
C3
cytarabine + daunorubicin + mitoxantrone
Sensitive: C3 – Early Trials
cytarabine + daunorubicin + mitoxantrone
Sensitive
:
C3
PTPN11 mutation
Acute Myelogenous Leukemia
PTPN11 mutation
Acute Myelogenous Leukemia
ivosidenib
Resistant: C3 – Early Trials
ivosidenib
Resistant
:
C3
ivosidenib
Resistant: C3 – Early Trials
ivosidenib
Resistant
:
C3
PTPN11 mutation
Acute Myelogenous Leukemia
PTPN11 mutation
Acute Myelogenous Leukemia
venetoclax + ABBV 075
Sensitive: C3 – Early Trials
venetoclax + ABBV 075
Sensitive
:
C3
venetoclax + ABBV 075
Sensitive: C3 – Early Trials
venetoclax + ABBV 075
Sensitive
:
C3
PTPN11 mutation
Non Small Cell Lung Cancer
PTPN11 mutation
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
nivolumab + ipilimumab
Sensitive
:
C3
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
nivolumab + ipilimumab
Sensitive
:
C3
PTPN11 mutation
Acute Myelogenous Leukemia
PTPN11 mutation
Acute Myelogenous Leukemia
azacitidine
Sensitive: C3 – Early Trials
azacitidine
Sensitive
:
C3
azacitidine
Sensitive: C3 – Early Trials
azacitidine
Sensitive
:
C3
PTPN11 mutation
Acute Myelogenous Leukemia
PTPN11 mutation
Acute Myelogenous Leukemia
azacitidine
Sensitive: C3 – Early Trials
azacitidine
Sensitive
:
C3
azacitidine
Sensitive: C3 – Early Trials
azacitidine
Sensitive
:
C3
PTPN11 mutation
Acute Myelogenous Leukemia
PTPN11 mutation
Acute Myelogenous Leukemia
dasatinib
Sensitive: D – Preclinical
dasatinib
Sensitive
:
D
dasatinib
Sensitive: D – Preclinical
dasatinib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login